Physician profile
Robert C Clements
NPI 1639143472
$2,802.84
in general payments reported to CMS, 2019-2025
19 companies · $1,521 in 2025
The $1,521 reported for 2025 was more than what 96% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $973 · 2024: $308 · 2025: $1,521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,205 · Long Term Medical Supply Or Device Loan: $624.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,204.96 |
| Long Term Medical Supply Or Device Loan | $624.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $973.41 | 2020 | |
| Integra Lifesciences Corporation | $624.47 | 2025 | Integra, Amnioexcel |
| Lilly USA, LLC | $223.54 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $183.92 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $159.52 | 2025 | Airsupra, Andexxa, Breztri |
| Novo Nordisk INC | $116.91 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Exact Sciences Corporation | $90.31 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $79.37 | 2024-2025 | Evenity, Prolia, Prolia |
| Otsuka America Pharmaceutical, INC. | $55.26 | 2024-2025 | Rexulti |
| Glaxosmithkline, LLC. | $46.53 | 2025 | Shingrix, Arexvy |
| Gilead Sciences, INC. | $44.03 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $33.78 | 2025 | |
| Abbvie INC. | $32.32 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.13 | 2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $24.24 | 2025 | Eliquis |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $23.84 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Merck Sharp & Dohme LLC | $22.24 | 2025 | Gardasil 9, Capvaxive |
| Kowa Pharmaceuticals America, INC. | $21.18 | 2025 | Zoryve |
| Rgh Enterprises LLC | $15.84 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Clements listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.